GSA Capital Partners LLP Decreases Position in OmniAb, Inc. (NASDAQ:OABI)

GSA Capital Partners LLP reduced its stake in shares of OmniAb, Inc. (NASDAQ:OABI) by 3.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 91,437 shares of the company’s stock after selling 3,015 shares during the quarter. GSA Capital Partners LLP owned 0.08% of OmniAb worth $387,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of OABI. Atria Investments Inc bought a new stake in shares of OmniAb in the 3rd quarter worth about $148,000. Rice Hall James & Associates LLC grew its stake in OmniAb by 6.4% in the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares in the last quarter. Palumbo Wealth Management LLC increased its holdings in OmniAb by 12.5% in the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after buying an additional 2,744 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after buying an additional 8,909 shares in the last quarter. Finally, CWC Advisors LLC. bought a new position in OmniAb during the 3rd quarter worth approximately $54,000. 72.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on OABI shares. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 price objective on shares of OmniAb in a research report on Friday, August 16th. Finally, Benchmark reissued a “buy” rating and set a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Trading Down 1.3 %

Shares of NASDAQ:OABI opened at $3.85 on Friday. The business’s 50 day moving average is $4.15 and its 200-day moving average is $4.25. The firm has a market capitalization of $454.92 million, a PE ratio of -6.21 and a beta of -0.12. OmniAb, Inc. has a 1-year low of $3.56 and a 1-year high of $6.72.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.